{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 47 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '7.3.4', 'Safety analyses', 'Analysis of adverse events will be restricted to nintedanib-related serious adverse events,', 'nintedanib-non-related serious adverse events and events of special interest.', 'Adverse events will be coded using the Medical Dictionary for Drug Regulatory Activities', '(MedDRA). Standard BI summary tables and listings will be produced. Adverse events with', 'an onset between start of pulmonary rehabilitation treatment and end of trial will be assigned', 'to the on-treatment period for evaluation. All randomized patients will be included in the', 'safety analysis. In general, safety analyses will be descriptive in nature and will be based on', 'BI standards. No hypothesis testing is planned.', 'Frequency, severity, and causal relationship of adverse events will be tabulated by system', 'organ class and preferred term after coding according to the current version of the Medical', 'Dictionary for Drug Regulatory Activities at the database lock.', 'Vital signs, physical examinations, or other safety-relevant data observed at screening,', 'baseline, during the course of the trial and at the end-of-trial evaluation will be assessed with', 'regard to possible changes compared to findings before start of pulmonary rehabilitation.', 'Analysis of laboratory data and electrocardiogram is not planned.', '7.3.5', 'Pharmacokinetic and Pharmacodynamic analyses', 'There is no pharmacokinetic analyses planned for this trial.', '7.4', 'INTERIM ANALYSES', 'No interim analysis is planned. A regular review of safety data will also be conducted to', 'monitor the safety of patients in the trial.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 48 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '7.5', 'HANDLING OF MISSING DATA', 'In efficacy analyses of continuous endpoints missing data will not be imputed. Multiple', 'imputation will be used as a sensitivity analysis to handle missing data. Detailed description', 'of multiple imputation will be included in the TSAP.', '7.6', 'RANDOMISATION', 'Patients will be randomized in blocks to pulmonary rehabilitation groups with an equal', 'probability of assignment to each treatment group (see Sections 4.1.2, 4.1.3 and 4.1.4 for', 'details). BI will arrange for the randomisation. The randomisation list will be generated using', 'an Interactive Response Technology (IRT), which involves a pseudo-random number', 'generator so that the resulting treatment will be both reproducible and non-predictable.', 'Access to the codes will be controlled and documented. The block size will be documented in', 'the clinical trial report.', '7.7', 'DETERMINATION OF SAMPLE SIZE', 'In the 1199.187 6-month data, an unadjusted mean for absolute change from baseline in', '6MWT distance of 4.9 meters (sd = 76.5) was observed for nintedanib. To conservatively', 'estimate the sample size, a standard deviation of 85.0 is used in estimation. In the 2014', 'Cochrane Database of Systematic Reviews [R18-1704], a mean for absolute change from', 'baseline in 6MWT distance of 44.3 meters was observed for pulmonary rehabilitation for', 'interstitial lung disease. The minimal clinically important difference for the 6MWD for IPF', 'patients with combined treatment of nintedanib and pulmonary rehabilitation versus IPF', 'patients treated with nintedanib only is 30 meters [R18-1767].', 'In light of the available evidence, at least 254 patients would be required to provide 80%', 'power to detect a difference in means of 30 meters between nintedanib and pulmonary', 'rehabilitation combination treatment versus nintedanib by itself with a two-sided type-I error', 'of 0.05. Assuming 10% drop out, at least 141 patients per arm, or 282 patients will be', 'required. Calculations were performed using nQuery Advisor\u00ae 6.1 statistical package by', 'Statistical Solutions Ltd. under the fixed term test of means with two groups option for', 'student t-test with equal variance.', 'Difference in', 'Common', 'Total N of', 'Standard', 'Power (%)', 'randomized', 'Means', 'Deviation', 'patients', '30.0', '77.0', '80', '210', '30.0', '85.0', '80', '254', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}